Filing Flows › Comparisons › EDIT vs DTIL
Editas Medicine vs Precision Biosciences: EDIT and DTIL compared
Editas Medicine is the larger company: $11.9M of revenue in its latest quarter (Q2 2026) against $10.8M for Precision Biosciences (Q3 FY26). Precision Biosciences is growing faster (374× against +232% a year earlier). Precision Biosciences is more profitable, with an operating margin of -83.7% against -156.0%.
Where the money goes: EDIT and DTIL
Editas Medicine (EDIT) · Q2 2026
Editas Medicine, Q2 2026: revenue $11.9M (+232% year over year), operating margin -156.0%, net loss $18.2M, operating cash flow −$29.6M. The chart follows the revenue to costs, profit and cash.
Precision Biosciences (DTIL) · Q3 FY26
Precision Biosciences, Q3 FY26: revenue $10.8M (374× year over year), operating margin -83.7%, net loss $18.4M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
| Editas Medicine (EDIT) | Precision Biosciences (DTIL) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 FY26 |
| Revenue | $11.9M | $10.8M |
| Revenue growth, Y/Y | +232% | 374× |
| Operating margin | -156.0% | -83.7% |
| Net earnings | −$18.2M | −$18.4M |
| Net margin | -153.3% | -170.2% |
| Operating cash flow | −$29.6M | −$11.9M |
Questions
Which is bigger, Editas Medicine or Precision Biosciences?
Editas Medicine is the larger company: $11.9M of revenue in its latest quarter (Q2 2026) against $10.8M for Precision Biosciences (Q3 FY26).
Is Editas Medicine or Precision Biosciences growing faster?
Precision Biosciences is growing faster (374× against +232% a year earlier).
Which is more profitable, Editas Medicine or Precision Biosciences?
Precision Biosciences is more profitable, with an operating margin of -83.7% against -156.0%.
More: Editas Medicine earnings · how Editas Medicine makes money · Precision Biosciences earnings · how Precision Biosciences makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed May 5, 2026). Fiscal quarters can end on different dates. Not investment advice.